Consumers Challenged AbbVie Price Fixing Lawsuit Dismissal
A federal appellate panel heard arguments to revive a class action lawsuit over alleged Humira price inflation.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should pharmaceutical companies face class action lawsuits for high drug prices under consumer protection laws?
Plaintiffs argued before a Seventh Circuit panel to revive a class action lawsuit that accuses AbbVie of inflating drug prices through undisclosed rebates. A lower court previously dismissed the case in January.
Why it matters
The litigation highlights concerns that AbbVie utilized shadow pricing and rebate schemes to keep costs artificially high, practices previously criticized by the House Oversight Committee as unjustified.
Humira generated $20 billion in annual global sales in 2021. The underlying class action complaint filed by plaintiffs spans 103 pages.
The players
AbbVie
This Chicago-based pharmaceutical company is the manufacturer of the blockbuster drug Humira.
Amgen
This biotechnology company is accused of engaging in shadow pricing strategies alongside AbbVie.
House Oversight Committee
This legislative body investigated pharmaceutical pricing practices and labeled specific industry methods as unfair and unsustainable.
The details
Plaintiffs claim AbbVie engaged in shadow pricing with Amgen, a strategy where competitors mirror price hikes rather than undercutting them. The suit alleges AbbVie paid undisclosed rebates to pharmacy benefit managers to secure formulary placement and published artificial list prices.
Timeline
A 2016 Amgen presentation outlined a strategy to follow AbbVie's pricing.
Humira reached $20 billion in global sales during 2021.
A lower court dismissed the lawsuit in January 2026.
Consumers presented their case to the Seventh Circuit panel on September 23, 2026.
Market Landscape
The lawsuit reflects a broader trend of increased legal scrutiny into pharmaceutical pricing strategies that prioritize market stability over competition. This case tests whether such coordinated pricing models can be challenged under existing antitrust frameworks.
The outcome of this case could influence future drug pricing transparency and the cost burden shifted to patients and pharmacy benefit plans. If the lawsuit proceeds, it may lead to changes in how major manufacturers interact with competitors and benefit managers.
The takeaway
This case underscores the persistent tension between competitive market theory and the complex rebate structures of the modern pharmaceutical industry. Consumers and policymakers remain focused on whether legal intervention can effectively curb practices that maintain high drug prices.
Further reading
For more context on legal and policy developments in the medical sector, visit the Healthcare section.
Source note: This article includes information reported by Court House News Service.
Live Poll
Should pharmaceutical companies face class action lawsuits for high drug prices under consumer protection laws?
